Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin effect on inflammatory cytokines and hs-CRP in NAFLD
IRCT2015052322381N1Phase 3Completed
- Sponsor
- Neyshabour University of Medical Sciences
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of curcumin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Neyshabour University of Medical Sciences. Primary endpoints: Change in serum levels of 12 inflammatory cytokines and Change in high-sensitivity C-reactive protein (hs-CRP). Started Jan 2017; status: completed.
02
Drugs
curcumin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT2015052322381N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015052322381N1.